IP/patents | GenomeWeb

IP/patents

The GeneReader will feature a new sequencing chemistry that Qiagen believes circumnavigates an ongoing IP dispute with Illumina and provides enhanced performance.

The Broad Institute has a shot to end the dispute by early 2017 but the more likely outcome is that the parties will argue over whether to fracture the CRISPR IP estate.

The email, which claimed the Broad Institute did not deserve key CRISPR patents, is one of several attention-grabbing items in newly released documents.  

Illumina follows Agilent, Life Technologies, Affymetrix, Siemens, and Luminex in settling lawsuits alleging infringement of US Patent No 7,064,197.

During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.

In its court filing, the company said Twist Founder and CEO Emily LeProust stole its technology and breached her confidentiality agreements.

The company has sued three companies in the UK and two in Poland alleging they infringed on the firm's non-invasive prenatal testing patents.

Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.

The company exited the NGS whole-genome analysis market a few years ago and is now focused on building a business around its core IP search technology.

Hologic said in its Form 10-Q that Enzo sued the firm in March alleging infringement of a patent related to labeled nucleotides for use as diagnostic tools.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.